Chronic myeloid leukemia (CML) harboring BCR/ABL-T315I mutation has been a challenging obstacle for targeted therapy due to the acquired resistance to tyrosine kinase inhibitor (TKI)-based therapy. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.